Company intelligence / Profile preview
BroadenBio Co., Ltd.
Beijing, Chinaen.broadenbio.com ↗
- Ownership
- Private
- Development stage
- Phase 1
01
Overview
BB-102, a FGFR4 antagonist, is in Phase 1 clinical trials for Advanced Malignant Solid Neoplasm and Liver Cancer in China as of December 29, 2022
- Therapeutic areas
- OncologyImmunology
- Modalities
- Small moleculesAntibodies
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
Request access →03
Partnerships
Actively exploring domestic and international collaboration
Beyond the preview
Go deeper on BroadenBio Co., Ltd..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BroadenBio Co., Ltd..